An index of frontier and emerging AI labs.
Bio / AI drug discovery
AI-for-natural-products drug discovery lab — trains foundation models on mass spectrometry data to map small molecules from nature to disease biology. Raised $130M+ Series C in 2025.
| Name | Enveda |
|---|---|
| Aliases | Enveda Biosciences |
| Space | Bio / AI drug discovery |
| Founded | 2019 |
| Latest valuation | —(rumored) |
| Stage | — |
| Status | active |
| HQ | Boulder |
| Founders | Viswa Colluru |
| Website | https://www.envedabio.com |
| Careers | https://www.envedabio.com/careers |
| — | |
| X / Twitter | — |
No funding events recorded.
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-03 | added | Enveda added to tracker | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Helical | — | 2024 |
| Insilico Medicine | — | 2014 |
| Reliant AI | — | 2023 |
| Isomorphic Labs | >$15B | 2021 |
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |